Brian Galvin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Brian Galvin has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Deirdre Mongan
Health Research Board, Dublin, Ireland
3 shared publications - Seán R. Millar
School of Public Health, University College Cork, Cork, Ireland
3 shared publications - Anne Doyle
Health Research Board, Dublin, Ireland
2 shared publications - Margaret Mary Brennan
Public Health and Primary Care, Trinity College Dublin, Dublin, Ireland
2 shared publications - Noel McCarthy
Public Health and Primary Care, School of Medicine, Trinity College Dublin, Russell Centre, Tallaght Cross West, D24 DH74 Dublin, Ireland
2 shared publications - Ana Sarasa-Renedo
Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain
1 shared publication
Latest Publications
- Open Access
- 23 September 2025
- Published by Elsevier in International Journal of Drug Policy
- Vol. 145, 105011
Hexahydrocannabinol (HHC) use and harms in Ireland: New findings from the 2024 European Web Survey on Drugs
- 23 September 2025
- Published by Elsevier in International Journal of Drug Policy
- Vol. 145, 105011
Open AccessHexahydrocannabinol (HHC) use and harms in Ireland: New findings from the 2024 European Web Survey on Drugs
- Open Access
- 4 February 2025
- Published by Elsevier in Child Abuse & Neglect
- Vol. 161, 107302
Longitudinal associations between childhood adversity and alcohol use behaviours in early adulthood: Examining the mediating roles of parental and peer relationships
- 4 February 2025
- Published by Elsevier in Child Abuse & Neglect
- Vol. 161, 107302
Open AccessLongitudinal associations between childhood adversity and alcohol use behaviours in early adulthood: Examining the mediating roles of parental and peer relationships
- Top Cited PapersOpen Access
- 2 January 2025
- Published by Springer Nature in European Journal of Futures Research
- Vol. 13 (1) , 1-12
The role of foresight in public policy: lessons from deliberative democracy and perspectival realism
Foresight plays an important role in public policy development. The foresight learning process brings together various actors in the policy community and incentivizes them to think about the future. It encourages new ways of thinking and approaches to strategy and is a practical approach to using the future to inform decisions and actions in the present. Foresight faces challenges in becoming embedded in the policy process. One of these challenges is in establishing its epistemic authority when compared to natural science and social science disciplines. This paper argues foresight can benefit from developments in political theory and philosophy of science. Democratic deliberation is an approach to public discourse which emphasizes pluralism in debate and provides a detailed account of how reason-giving can add epistemic depth to foresight’s contribution to policy. Perspectival realism is a theory in philosophy of science which identifies the interplay between separate epistemic communities as the key mechanism in scientific development. The modal models that these epistemic communities create present a new way of understanding foresight’s study of the future and its part in the weave of scientific evidence, opinion and analysis that constitute policy development in a democratic society.
- 2 January 2025
- Published by Springer Nature in European Journal of Futures Research
- Vol. 13 (1) , 1-12
Top Cited PapersOpen AccessThe role of foresight in public policy: lessons from deliberative democracy and perspectival realism
Foresight plays an important role in public policy development. The foresight learning process brings together various actors in the policy community and incentivizes them to think about the future. It encourages new ways of thinking and approaches to strategy and is a practical approach to using the future to inform decisions and actions in the present. Foresight faces challenges in becoming embedded in the policy process. One of these challenges is in establishing its epistemic authority when compared to natural science and social science disciplines. This paper argues foresight can benefit from developments in political theory and philosophy of science. Democratic deliberation is an approach to public discourse which emphasizes pluralism in debate and provides a detailed account of how reason-giving can add epistemic depth to foresight’s contribution to policy. Perspectival realism is a theory in philosophy of science which identifies the interplay between separate epistemic communities as the key mechanism in scientific development. The modal models that these epistemic communities create present a new way of understanding foresight’s study of the future and its part in the weave of scientific evidence, opinion and analysis that constitute policy development in a democratic society.
- Open Access
- 1 November 2024
- Published by Elsevier in Addictive Behaviors
- Vol. 161, 108194
Associations and mediating factors between adverse childhood experiences and substance use behaviours in early adulthood: A population-based longitudinal study
- 1 November 2024
- Published by Elsevier in Addictive Behaviors
- Vol. 161, 108194
Open AccessAssociations and mediating factors between adverse childhood experiences and substance use behaviours in early adulthood: A population-based longitudinal study
- Open Access
- 22 April 2017
- Published by Springer Nature in Harm Reduction Journal
- Vol. 14 (1) , 1-14
Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus study
Despite advances in our knowledge of effective services for people who use drugs over the last decades globally, coverage remains poor in most countries, while quality is often unknown. This paper aims to discuss the historical development of successful epidemiological indicators and to present a framework for extending them with additional indicators of coverage and quality of harm reduction services, for monitoring and evaluation at international, national or subnational levels. The ultimate aim is to improve these services in order to reduce health and social problems among people who use drugs, such as human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infection, crime and legal problems, overdose (death) and other morbidity and mortality. The framework was developed collaboratively using consensus methods involving nominal group meetings, review of existing quality standards, repeated email commenting rounds and qualitative analysis of opinions/experiences from a broad range of professionals/experts, including members of civil society and organisations representing people who use drugs. Twelve priority candidate indicators are proposed for opioid agonist therapy (OAT), needle and syringe programmes (NSP) and generic cross-cutting aspects of harm reduction (and potentially other drug) services. Under the specific OAT indicators, priority indicators included ‘coverage’, ‘waiting list time’, ‘dosage’ and ‘availability in prisons’. For the specific NSP indicators, the priority indicators included ‘coverage’, ‘number of needles/syringes distributed/collected’, ‘provision of other drug use paraphernalia’ and ‘availability in prisons’. Among the generic or cross-cutting indicators the priority indicators were ‘infectious diseases counselling and care’, ‘take away naloxone’, ‘information on safe use/sex’ and ‘condoms’. We discuss conditions for the successful development of the suggested indicators and constraints (e.g. funding, ideology). We propose conducting a pilot study to test the feasibility and applicability of the proposed indicators before their scaling up and routine implementation, to evaluate their effectiveness in comparing service coverage and quality across countries. The establishment of an improved set of validated and internationally agreed upon best practice indicators for monitoring harm reduction service will provide a structural basis for public health and epidemiological studies and support evidence and human rights-based health policies, services and interventions.
- 22 April 2017
- Published by Springer Nature in Harm Reduction Journal
- Vol. 14 (1) , 1-14
Open AccessMonitoring quality and coverage of harm reduction services for people who use drugs: a consensus study
Despite advances in our knowledge of effective services for people who use drugs over the last decades globally, coverage remains poor in most countries, while quality is often unknown. This paper aims to discuss the historical development of successful epidemiological indicators and to present a framework for extending them with additional indicators of coverage and quality of harm reduction services, for monitoring and evaluation at international, national or subnational levels. The ultimate aim is to improve these services in order to reduce health and social problems among people who use drugs, such as human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infection, crime and legal problems, overdose (death) and other morbidity and mortality. The framework was developed collaboratively using consensus methods involving nominal group meetings, review of existing quality standards, repeated email commenting rounds and qualitative analysis of opinions/experiences from a broad range of professionals/experts, including members of civil society and organisations representing people who use drugs. Twelve priority candidate indicators are proposed for opioid agonist therapy (OAT), needle and syringe programmes (NSP) and generic cross-cutting aspects of harm reduction (and potentially other drug) services. Under the specific OAT indicators, priority indicators included ‘coverage’, ‘waiting list time’, ‘dosage’ and ‘availability in prisons’. For the specific NSP indicators, the priority indicators included ‘coverage’, ‘number of needles/syringes distributed/collected’, ‘provision of other drug use paraphernalia’ and ‘availability in prisons’. Among the generic or cross-cutting indicators the priority indicators were ‘infectious diseases counselling and care’, ‘take away naloxone’, ‘information on safe use/sex’ and ‘condoms’. We discuss conditions for the successful development of the suggested indicators and constraints (e.g. funding, ideology). We propose conducting a pilot study to test the feasibility and applicability of the proposed indicators before their scaling up and routine implementation, to evaluate their effectiveness in comparing service coverage and quality across countries. The establishment of an improved set of validated and internationally agreed upon best practice indicators for monitoring harm reduction service will provide a structural basis for public health and epidemiological studies and support evidence and human rights-based health policies, services and interventions.